Search Videos and More
News
Advancing New Treatments for Uncommon Cancer Subtypes
The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.
Symposium
2022 ESMO Congress Research Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review research highlights from the ESMO Congress 2022 held in Paris, France, September 9-13, 2022.
News
For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of Frailty
A new tool developed by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital outperforms conventional methods for predicting whether certain medications are likely to lead to frailty in older patients with blood cancers who are taking multiple medications, a study being published online today indicates.
News
In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program
The Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.
News
Online Testing Tool Identifies People Likely to Benefit from Genetic Testing for Inherited Risk for Certain Cancers
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, a new study shows.
News
Bispecific Antibodies Continue the Promise of Immunotherapy
Until recently, when adults with acute lymphocytic leukemia (ALL) weren't cured or put into prolonged remission by standard chemotherapy, "there really was no good treatment option," says Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute.
News
The Power of Plus: Combining Immunotherapy With Other Treatments is Showing Great Promise Against a Variety of Cancers
Even heroes need partners. As researchers are discovering, immunotherapy — the avatar of a new approach to cancer treatment — often works better when paired with other types of therapy.
News
Dana-Farber Research Publications
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Document
ESMO Congress 2022 Preview
Preview Studies and Symposia Featuring Dana-Farber Faculty
Document
Identification & Management of Lynch Syndrome in Clinical Practice
This conference will educate attendees on state-of-the-art approaches to managing individuals with known or suspected Lynch syndrome, a common, inherited form of cancer predisposition.
News
New Breast Cancer Clinical Trials
In the Breast Oncology Program at Dana-Farber Brigham Cancer Center, we offer breast cancer patients access to more than 50 clinical trials at a time — many of which are changing the standard of care worldwide and are not available elsewhere. We offer clinical trials for patients at all stages of their cancer journey, in the curative and metastatic settings, and welcome patients with any stage or subtype of disease.
News
2022 Master Class for Oncologists
Register here for the latest practices and guidelines in medical oncology. We look forward to bringing learners together again with expert faculty presentations and interactive panel discussions.